Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study

Basic Details
Date
Wednesday, November 1, 2017
Type
Publication
Medical Product
anti-diabetic agent (ADA)
dipeptidyl peptidase-4 (DPP-4) inhibitor
glimepiride
glipizide
glyburide
hypoglycemic drug
long-acting insulin
pioglitazone
saxagliptin
sitagliptin
sulfonylurea
thiazolidinedione
Health Outcome(s)
acute myocardial infarction (AMI)
Description

The cardiovascular safety of saxagliptin, a dipeptidyl-peptidase 4 inhibitor, compared with other antihyperglycemic treatments is not well understood. This article prospectively examined the association between saxagliptin use and acute myocardial infarction (AMI). The authors did not find a higher AMI risk in saxagliptin users compared with users of other selected antihyperglycemic agents during the first 5 years after U.S. Food and Drug Administration approval of the drug.

Author(s)

Sengwee Toh ScD; Marsha E. Reichman PhD; David J. Graham MD, MPH; Christian Hampp PhD; Rongmei Zhang PhD; Melissa G. Butler PharmD PhD; Aarthi Iyer MPH; Malcolm Rucker MS; Madelyn Pimentel BA; Jack Hamilton; Samuel Lendle; Bruce H. Fireman MA; the Mini-Sentinel Saxagliptin-AMI Surveillance Writing Group